RecruitingPhase 3NCT05008809

Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)

Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer Prospective, Randomized, Open, Multicenter Phase III Trial to Investigate the Efficacy of Active Post-resection/Ablation Therapy in Patients With Metastatic Colorectal Cancer


Sponsor

Dominik Paul Modest

Enrollment

507 participants

Start Date

Dec 6, 2021

Study Type

INTERVENTIONAL

Summary

This is an open-label, randomized, controlled, multicenter, phase III study with two parallel arms. Patients with metastatic colorectal cancer after definite interventional therapy of all lesions are randomized in a 2:1 fashion (favoring active therapy) to investigate the efficacy, patient reported quality of life and safety of mFOLFOXIRI/mFOLFOX-6 as additive treatment (Arm A) versus active follow-up/surveillance (Arm B).


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether giving chemotherapy after surgery or ablation (tumor destruction) to remove colorectal cancer that has spread (metastatic) prolongs the time before the cancer returns. It randomly assigns patients to receive post-treatment chemotherapy or just observation. **You may be eligible if...** - You are 18 or older with colorectal cancer (adenocarcinoma) - You have had surgery or ablation to successfully remove or destroy all colorectal cancer metastases (spread to other organs), with the original tumor also removed - Surgery/ablation was completed within the past 3–10 weeks - You have no major wound-healing problems **You may NOT be eligible if...** - You still have detectable cancer remaining after treatment - Your recovery from surgery is incomplete - You have not had the primary colorectal tumor removed Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGmFOLFOX6

Oxaliplatin: 85 mg/m², 2h IV infusion on d1 Folinic acid: 400 mg/m², 1-2 h IV infusion on d1 5-FU: (optional: 400 mg/m² bolus, 2-5 min IV infusion), 2400 mg/m², 46 h IV infusion on d1 Cycles are repeated on day 15. A total of up to 12 cycles are administered.

DRUGmFOLFOXIRI

Oxaliplatin: 85 mg/m², 2h IV infusion on d1 Irinotecan: 150 mg/m², 90 min IV infusion on d1 Folinic acid: 400 mg/m², 1-2 h IV infusion on d1 5-FU: 2400 mg/m², 46 h IV infusion on d1 Cycles are repeated on day 15. A total of up to 12 cycles are administered.

DRUGFOLFIRI

Folinic acid: 400mg/m², 1-2h IV Infusion on d1 5-FU: 2400 mg/m², 46 h IV infusion on d1 Irinotecan: 180 mg/m², 90-120 min IV infusion on d1 Cycles are repeated on day 15. A total of up to 12 cycles is administered.

DRUGCAPOX

Capecitabine: 1000 mg/m², oral 1-0-1 on d1-14 Oxaliplatin: 130 mg/m², 3h IV infusion on d1 Cycles are repeated on day 22. A total of up to 8 cycles isadministered.


Locations(79)

Klinikum St. Marien Amberg

Amberg, Germany

Helios Klinikum Bad Saarow

Bad Saarow, Germany

Klinikum Bayreuth

Bayreuth, Germany

Charité Universitätsmedizin Berlin

Berlin, Germany

Helios Klinikum Emil von Behring

Berlin, Germany

MVZ Onkologischer Schwerpunkt am Oskar-Helene-Heim

Berlin, Germany

Vivantes Klinikum am Urban Berlin

Berlin, Germany

Vivantes Klinikum Spandau Berlin

Berlin, Germany

St. Josef-Hospital Bochum

Bochum, Germany

Johanniterkrankenhaus Bonn

Bonn, Germany

Diakonie-Krankenhaus Bremen

Bremen, Germany

Klinikum Chemnitz

Chemnitz, Germany

Kliniken der Satdt Köln

Cologne, Germany

Klinikum Darmstadt

Darmstadt, Germany

DONAUISAR Klinikum Deggendorf

Deggendorf, Germany

Städtisches Klinikum Dessau

Dessau, Germany

Onkologische-Gemeinschaftspraxis Dresden

Dresden, Germany

Onkozentrum Dresden

Dresden, Germany

Universitätsklinikum Düsseldorf

Düsseldorf, Germany

Kliniken Essen-Mitte

Essen, Germany

Universitätsklinikum Essen

Essen, Germany

KHNW Frankfurt

Frankfurt, Germany

Markus-Krankenhaus Frankfurt

Frankfurt, Germany

Universitätsklinikum Frankfurt

Frankfurt, Germany

Universitätsklinikum Freiburg

Freiburg im Breisgau, Germany

Gemeinschaftspraxis internistische Onkologie Fürth

Fürth, Germany

Niels-Stensen Kliniken Georgsmarienhütte

Georgsmarienhütte, Germany

Praxis Hämatologie Onkologie Gießen

Giessen, Germany

Universitätsmedizin Göttingen

Göttingen, Germany

Universitätsklinikum Halle

Halle, Germany

Universitätsklinikum Hamburg-Eppendorf

Hamburg, Germany

Medizinische Hochschule Hannover

Hanover, Germany

St. Anna Hospital Herne

Herne, Germany

Universitätsklinikum des Saarlandes

Homburg, Germany

Klinikum Ingolstadt GmbH

Ingolstadt, Germany

Universitätsklinikum Jena

Jena, Germany

Klinikum Landshut

Landshut, Germany

VK&K Studien Landshut

Landshut, Germany

Studienzentrum UnterEms Leer

Leer, Germany

Universitätsklinikum Leipzig

Leipzig, Germany

Klinikum Leverkusen

Leverkusen, Germany

Klinikum Lippe

Lippe, Germany

Klinikum Ludwigsburg

Ludwigsburg, Germany

Klinikum Magdeburg

Magdeburg, Germany

Universitätsmedizin Mainz

Mainz, Germany

OnkoNet Marburg GmbH

Marburg, Germany

Philipps-Universität Marburg

Marburg, Germany

Johannes Wesling Klinikum Minden

Minden, Germany

Kliniken Maria Hilf Mönchengladbach

Mönchengladbach, Germany

Klinikum der Universität München

München, Germany

Klinikum rechts der Isar TU München

München, Germany

München Klinik Bogenhausen

München, Germany

München Klinik Neuperlach

München, Germany

Gemeinschaftspraxis Münster

Münster, Germany

Universitätsklinikum Münster

Münster, Germany

Friedrich-Ebert-Krankenhaus Neumünster

Neumünster, Germany

Lukaskrankenhaus Neuss

Neuss, Germany

Klinikum Nürnberg

Nuremberg, Germany

Pi.Tri-Studien GmbH Offenburg

Offenburg, Germany

Klinikum Passau

Passau, Germany

Schwerpunktpraxis Penzberg

Penzberg, Germany

Ernst von Bergmann Klinikum Potsdam

Potsdam, Germany

Studienzentrum Onkologie Ravensburg

Ravensburg, Germany

Krankenhaus Barmherzige Brüder Regensburg

Regensburg, Germany

Universitätsklinikum Regensburg

Regensburg, Germany

Kreiskliniken Reutlingen

Reutlingen, Germany

Mathias Spital Rheine

Rheine, Germany

RoMed Klinikum Rosenheim

Rosenheim, Germany

Universitätsmedizin Rostock

Rostock, Germany

DIAK Klinikum Schwäbisch Hall

Schwäbisch Hall, Germany

Marienkrankenhaus Siegen

Siegen, Germany

Klinikum Stuttgart

Stuttgart, Germany

Marienhospital Stuttgart

Stuttgart, Germany

Krankenhaus der Barmherzigen Brüder Trier

Trier, Germany

Universitätsklinikum Ulm

Ulm, Germany

Klinikum Wetzlar

Wetzlar, Germany

Onkologisches Zentrum Wolfsburg-Helmstedt

Wolfsburg, Germany

Petrus-Krankenhaus Wuppertal

Wuppertal, Germany

Gemeinschaftspraxis Würzburg

Würzburg, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05008809